Imfinzi (durvalumab) vs Bavencio (avelumab)
Imfinzi (durvalumab) vs Bavencio (avelumab)
Imfinzi (durvalumab) and Bavencio (avelumab) are both immune checkpoint inhibitors, but they target the PD-L1 protein in slightly different ways, which can influence their effectiveness and side-effect profiles in treating certain cancers. Imfinzi is approved for use in the treatment of urothelial carcinoma and extensive-stage small cell lung cancer, as well as unresectable, stage III non-small cell lung cancer after chemoradiation therapy. Bavencio, on the other hand, is approved for Merkel cell carcinoma, a rare skin cancer, urothelial carcinoma, and renal cell carcinoma as a first-line maintenance treatment. The choice between these medications should be made in consultation with an oncologist, considering the specific type of cancer, patient's overall health, and potential side effects.
Difference between Imfinzi and Bavencio
| Metric | Imfinzi (durvalumab) | Bavencio (avelumab) |
|---|---|---|
| Generic name | Durvalumab | Avelumab |
| Indications | Urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer | Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma |
| Mechanism of action | PD-L1 inhibitor | PD-L1 inhibitor |
| Brand names | Imfinzi | Bavencio |
| Administrative route | Intravenous | Intravenous |
| Side effects | Fatigue, musculoskeletal pain, constipation, decreased appetite, nausea, peripheral edema, urinary tract infection | Fatigue, musculoskeletal pain, diarrhea, nausea, infusion-related reaction, rash, decreased appetite |
| Contraindications | Hypersensitivity to durvalumab or any of its excipients | Hypersensitivity to avelumab or any of its excipients |
| Drug class | Anti-PD-L1 monoclonal antibody | Anti-PD-L1 monoclonal antibody |
| Manufacturer | AstraZeneca | EMD Serono (Merck KGaA) and Pfizer |
Efficacy
Imfinzi (Durvalumab) Efficacy in Urothelial Carcinoma
Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody that has shown efficacy in the treatment of urothelial carcinoma. Durvalumab is used for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Clinical trials, such as the Phase III DANUBE trial, have evaluated the efficacy of durvalumab in this patient population. Results have demonstrated that durvalumab can lead to a meaningful improvement in overall survival in some patients, particularly those with high PD-L1 expression.
Moreover, durvalumab has been studied as a monotherapy and in combination with other therapeutic agents. The combination of durvalumab with other immunotherapies or targeted therapies is an area of active investigation, with the aim of improving response rates and outcomes for patients with urothelial carcinoma. The use of durvalumab is associated with a manageable safety profile, and it has been approved by regulatory agencies in multiple countries for the treatment of urothelial carcinoma based on the strength of clinical trial data.
Bavencio (Avelumab) Efficacy in Urothelial Carcinoma
Bavencio (avelumab) is another PD-L1 inhibitor that has demonstrated efficacy in the treatment of urothelial carcinoma. Avelumab is approved for patients with locally advanced or metastatic urothelial carcinoma who have not responded to prior platinum-containing chemotherapy. The approval of avelumab for this indication was based on the results of the JAVELIN Solid Tumor trial, a multicenter, single-arm, open-label, Phase I study that showed avelumab can induce partial or complete tumor responses in a subset of patients.
The efficacy of avelumab in urothelial carcinoma has been further supported by additional clinical studies, which have shown that avelumab can provide durable responses and has the potential to extend overall survival in some patients. As with durvalumab, ongoing research is focused on evaluating avelumab in combination with other therapeutic agents to enhance its efficacy. Avelumab's safety profile is also considered manageable, and it is an important treatment option for patients with urothelial carcinoma who have limited responses to traditional chemotherapy.
Regulatory Agency Approvals
Imfinzi
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Bavencio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
-
Therapeutic Goods Administration (TGA), Australia
Access Imfinzi or Bavencio today
If Imfinzi or Bavencio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us